Cancer-germline genes are a class of genes that are normally expressed in testis, trophoblast and few somatic tissues but abnormally expressed in tumor tissues. Their expression signature indicates that they can induce cellular immune responses, thus being applied as targets in cancer immunotherapy.
OBJECTIVES:
To obtain the data of cellular immune responses against cancer-germline genes in cancer.
METHODS:
We searched PubMed/Medline with the key words cancer-germline antigen, cancer-testis antigen, CD4 T cell, CD8 T cell and cancer.
RESULTS:
About 40 cancer-germline genes have been shown to induce T cell specific responses in cancer patients. Melanoma, lung and breast cancer are among the mostly assessed cancer types. Several epitopes have been identified which can be used in immunotherapy of cancer.
CONCLUSION:
Cellular immune responses against cancer-germline genes are indicative of appropriateness of these genes as therapeutic targets.
Ghafouri-FardS. and ModarressiM.H., Cancer-testis antigens: potential targets for cancer immunotherapy, Archives of Iranian Medicine12 (Jul, 2009), 395.
2.
DianatpourM. et al., Expression of testis specific genes TSGA10, TEX101 and ODF3 in breast cancer, Iranian Red Crescent Medical Journal14 (Nov, 2012), 722.
3.
AdemuyiwaF.O. et al., NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer, PloS One7 (2012), e38783.
4.
Ghafouri-FardS.Ousati AshtianiZ.Sabah GolianB.HasheminasabS.M. and ModarressiM.H., Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer, Archives of Medical Research41 (Apr, 2010), 195.
5.
Ghafouri-FardS. et al., Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features, British Journal of Dermatology162 (2010), 772.
6.
Ghafouri-FardS.NekooheshL. and MotevaseliE., Bladder cancer biomarkers: review and update, Asian Pac J Cancer P15 (2014), 2395.
7.
Taherian-EsfahaniZ. et al., Cancer-testis antigens: a novel group of tumor biomarkers in ovarian cancers, Iran J Cancer Prev9 (Dec, 2016).
8.
YazarlouF. et al., Expression analysis of a panel of cancer-testis antigens in bladder cancer, Pers Med15 (Nov, 2018), 511.
9.
RosenzweigM.A. et al., Cancer-testis antigen expression and immunogenicity in AL amyloidosis, Blood Cancer Journal2 (Sep 14, 2012), e90.
10.
AyyoubM. et al., The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma, Cancer Immunity Archive4 (2004), 7.
11.
TabarestaniS. and Ghafouri-FardS., Cancer stem cells and response to therapy, Asian Pac J Cancer P13 (2012), 5947.
12.
Kazemi-OulaG.Ghafouri-FardS.MobasheriM.B.GeranpayehL. and ModarressiM.H., Upregulation of RHOXF2 and ODF4 expression in breast cancer tissues, Cell Journal (Yakhteh)17 (2015), 471.
13.
AziziF. and Ghafouri-FardS., Outer dense fiber proteins: bridging between male infertility and cancer, Archives of Iranian Medicine20 (May, 2017), 320.
14.
Seifi-AlanM. et al., Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines, Asian Pac J Cancer P14 (2013), 6625.
15.
Ghafouri-FardS.ModarressiM.H. and YazarlooF., Expression of testis-specific genes, TEX101 and ODF4, in chronic myeloid leukemia and evaluation of TEX101 immunogenicity, Ann Saudi Med32 (May–Jun, 2012), 256.
16.
BabatundeK.A.NajafiA.SalehipourP.ModarressiM.H. and MobasheriM.B., Cancer/testis genes in relation to sperm biology and function, Iran J Basic Med Sci20 (Sep, 2017), 967.
17.
Ghafouri-FardS., Expression of cancer-testis antigens in pediatric cancers, Asian Pac J Cancer Prev16 (2015), 5149.
18.
YazarlouF. et al., Urine exosome gene expression of cancer-testis antigens for prediction of bladder carcinoma, Cancer Management and Research10 (2018), 5373.
19.
JagerE. et al., Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes, The Journal of Experimental Medicine187 (Jan 19, 1998), 265.
20.
Ghafouri-FardS.RezazadehF.Zare-AbdollahiD.OmraniM.D. and MovafaghA., Are so-called cancer-testis genes expressed only in testis? Asian Pac J Cancer Prev15 (2014), 7703.
21.
OkumuraH. et al., Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells, Microbiology and Immunology49 (2005), 1009.
22.
Chiriva-InternatiM. et al., Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer, The Prostate72 (Jan, 2012), 12.
23.
BoëlP. et al., BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes, Immunity2 (1995), 167.
24.
MonjiM. et al., Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses, Clinical Cancer Research10 (2004), 6047.
25.
HaraoM. et al., HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL, International Journal of Cancer123 (2008), 2616.
26.
InodaS. et al., Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma, Journal of Immunotherapy32 (2009), 474.
27.
JanjicB. et al., Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers, The Journal of Immunology177 (2006), 2717.
28.
AarnoudseC.A.van den DoelP.B.HeemskerkB. and SchrierP.I., Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1, International Journal of Cancer82 (Jul 30, 1999), 442.
29.
RimoldiD. et al., Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma, Journal of Immunology (Baltimore, Md.: 1950)165 (Dec 15, 2000), 7253.
30.
WangR.F. et al., A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames, Journal of Immunology (Baltimore, Md.: 1950)161 (Oct 1, 1998), 3598.
31.
SunZ. et al., A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors, Cancer Immunology, Immunotherapy: CII55 (Jun, 2006), 644.
32.
SlagerE.H. et al., Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber, Cancer Gene Therapy11 (Mar, 2004), 227.
33.
ZengG.WangX.RobbinsP.F.RosenbergS.A. and WangR.F., CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production, Proceedings of the National Academy of Sciences of the United States of America98 (Mar 27, 2001), 3964.
34.
SlagerE.H. et al., Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes, Journal of Immunology (Baltimore, Md.: 1950)172 (Apr 15, 2004), 5095.
35.
JagerE. et al., Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma, The Journal of Experimental Medicine191 (Feb 21, 2000), 625.
36.
SlagerE.H. et al., CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame, Journal of Immunology (Baltimore, Md.: 1950)170 (Feb 1, 2003), 1490.
37.
WangH.Y. et al., Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy, Immunity20 (Jan, 2004), 107.
38.
HasegawaK. et al., In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research12 (Mar 15, 2006), 1921.
39.
OchsenreitherS. et al., Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen, Blood119 (Jun 7, 2012), 5492.
40.
Van den EyndeB. et al., A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma, The Journal of Experimental Medicine182 (Sep 1, 1995), 689.
41.
KonoK. et al., Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer, Cancer Science100 (Aug, 2009), 1502.
42.
ChenG. et al., Serological identification of immunogenic antigens in acute monocytic leukemia, Leukemia Research29 (May, 2005), 503.
43.
ZhouF.L.ZhangW.G.MengX.ChenG. and WangJ.L., Bioinformatic analysis and identification for a novel antigen MLAA-22 in acute monocytic leukemia, Zhongguo Shi Yan Xue Ye Xue Za Zhi16 (Jun, 2008), 466.
44.
SudaT.TsunodaT.DaigoY.NakamuraY. and TaharaH., Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy, Cancer Science98 (Nov, 2007), 1803.
45.
TraversariC. et al., A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E, The Journal of Experimental Medicine176 (Nov 1, 1992), 1453.
46.
OttavianiS.ZhangY.BoonT. and van der BruggenP., A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells, Cancer Immunology, Immunotherapy: CII54 (Dec, 2005), 1214.
47.
ChauxP. et al., Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1, Journal of Immunology (Baltimore, Md.: 1950)163 (Sep 1, 1999), 2928.
48.
LuitenR. and van der BruggenP., A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes, Tissue Antigens55 (Feb, 2000), 149.
49.
LuitenR.M.DemotteN.TineJ. and van der BruggenP., A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules, Tissue Antigens56 (Jul, 2000), 77.
50.
TanzarellaS. et al., Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family, Cancer Res59 (Jun 1, 1999), 2668.
51.
CorbiereV. et al., Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors, Tissue Antigens63 (May, 2004), 453.
52.
van der BruggenP. et al., Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601, European Journal of Immunology24 (Sep, 1994), 2134.
53.
WangX.F. et al., Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family, Cancer Immunology, Immunotherapy: CII56 (Jun, 2007), 807.
54.
ChauxP. et al., Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes, The Journal of Experimental Medicine189 (Mar 1, 1999), 767.
55.
ChauxP. et al., A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells, European Journal of Immunology31 (Jun, 2001), 1910.
56.
HuangL.Q. et al., Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma, Journal of Immunology (Baltimore, Md.: 1950)162 (Jun 1, 1999), 6849.
57.
van der BruggenP. et al., A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3, European Journal of Immunology24 (Dec, 1994), 3038.
58.
HeideckerL. et al., Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12, Journal of Immunology (Baltimore, Md.: 1950)164 (Jun 1, 2000), 6041.
59.
BreckpotK.HeirmanC.De GreefC.van der BruggenP. and ThielemansK., Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses, Journal of Immunology (Baltimore, Md.: 1950)172 (Feb 15, 2004), 2232.
60.
AkiyamaY. et al., Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay, Cancer Immunology, Immunotherapy: CII61 (Dec, 2012), 2311.
61.
KawashimaI. et al., The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors, Human Immunology59 (Jan, 1998), 1.
62.
TaharaK. et al., Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research5 (Aug, 1999), 2236.
63.
GoodyearO.C. et al., Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma, Blood112 (Oct 15, 2008), 3362.
64.
GauglerB. et al., Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes, The Journal of Experimental Medicine179 (Mar 1, 1994), 921.
65.
OisoM. et al., A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes, International Journal of Cancer81 (May 5, 1999), 387.
66.
MiyagawaN. et al., A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells, Oncology70 (2006), 54.
67.
BilsboroughJ. et al., A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18, Tissue Antigens60 (Jul, 2002), 16.
68.
SchultzE.S. et al., A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes, Tissue Antigens57 (Feb, 2001), 103.
69.
SchultzE.S. et al., The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome, The Journal of Experimental Medicine195 (Feb 18, 2002), 391.
70.
HermanJ. et al., A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3, Immunogenetics43 (1996), 377.
71.
RussoV. et al., Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response, Proceedings of the National Academy of Sciences of the United States of America97 (Feb 29, 2000), 2185.
72.
SchultzE.S. et al., A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes, Cancer Res60 (Nov 15, 2000), 6272.
73.
SchultzE.S. et al., Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy, Journal of Immunology (Baltimore, Md.: 1950)172 (Jan 15, 2004), 1304.
74.
ZhangY. et al., A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein, Journal of Immunology (Baltimore, Md.: 1950)171 (Jul 1, 2003), 219.
75.
KobayashiH.SongY.HoonD.S.AppellaE. and CelisE., Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles, Cancer Res61 (Jun 15, 2001), 4773.
76.
ConsognoG. et al., Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3, Blood101 (Feb 1, 2003), 1038.
77.
ManiciS. et al., Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11, The Journal of Experimental Medicine189 (Mar 1, 1999), 871.
78.
CessonV. et al., MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes, Cancer Immunology, Immunotherapy: CII60 (Jan, 2011), 23.
79.
KobayashiT. et al., New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells, Tissue Antigens62 (Nov, 2003), 426.
80.
DuffourM.T. et al., A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes, European Journal of Immunology29 (Oct, 1999), 3329.
81.
MiyaharaY. et al., Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research11 (Aug 1, 2005), 5581.
82.
ZhangY.StroobantV.RussoV.BoonT. and van der BruggenP., A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes, Tissue Antigens60 (Nov, 2002), 365.
83.
AndersonL.D. et al., Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma, Cancer Immunology, Immunotherapy60 (2011), 985.
84.
GermeauC. et al., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, Journal of Experimental Medicine201 (2005), 241.
85.
XingQ. et al., Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587, Biochemical and Biophysical Research Communications372 (2008), 331.
86.
MaW. et al., Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2, International Journal of Cancer109 (2004), 698.
87.
GodelaineD. et al., A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44, Cancer Immunology, Immunotherapy56 (2007), 753.
88.
GnjaticS. et al., NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer, International Journal of Cancer127 (2010), 381.
89.
ObaraW. et al., Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer, Japanese Journal of Clinical Oncology42 (2012), 591.
90.
NakamuraY. et al., Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity, Lung Cancer65 (2009), 119.
91.
MatsuzakiJ. et al., Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proceedings of the National Academy of Sciences107 (2010), 7875.
92.
NishikawaH. et al., Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma, Blood119 (2012), 3097.
93.
ToorA.A. et al., Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity, British Journal of Haematology158 (2012), 700.
94.
GuptaA. et al., A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy, Cancer Immunity Archive13 (2013), 3.
95.
FujitaS. et al., NY-ESO-1 expression and immunogenicity in esophageal cancer, Clinical Cancer Research10 (2004), 6551.
96.
NakadaT. et al., NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer, Cancer Immunity Archive3 (2003), 10.
97.
KorangyF. et al., Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma, Clinical Cancer Research10 (2004), 4332.
98.
ShangX.-Y. et al., The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients, Clinical Cancer Research10 (2004), 6946.
99.
YokokawaJ. et al., Identification of cytotoxic T-lymphocyte epitope (s) and its agonist epitope (s) of a novel target for vaccine therapy (PAGE4), International Journal of Cancer121 (2007), 595.
100.
Ait-TaharK. et al., Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma, British Journal of Haematology146 (2009), 396.
101.
Ait-TaharK. et al., CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma, haematologica96 (2011), 78.
102.
LiuW. et al., Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer, Amino Acids42 (2012), 2257.
103.
IkedaH. et al., Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity6 (1997), 199.
104.
GriffioenM. et al., Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy, Clinical Cancer Research12 (2006), 3130.
105.
RezvaniK. et al., Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia, Blood113 (2009), 2245.
106.
QuintarelliC. et al., High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells, Blood117 (2011), 3353.
107.
Chiriva-InternatiM. et al., Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk, European Journal of Immunology31 (2001), 2277.
108.
Chiriva-InternatiM.WangZ.SalatiE.TimminsP. and LimS.H., Tumor vaccine for ovarian carcinoma targeting sperm protein 17, Cancer: Interdisciplinary International Journal of the American Cancer Society94 (2002), 2447.
109.
Chiriva-InternatiM.WangZ.PochopienS.SalatiE. and LimS.H., Identification of a sperm protein 17 CTL epitope restricted by HLA-A1, International Journal of Cancer107 (2003), 863.
110.
Chiriva-InternatiM. et al., A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17, Journal of Immunological Methods321 (2007), 86.
111.
FrankC.HundemerM.HoA.D.GoldschmidtH. and Witzens-HarigM., Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma, Leukemia & Lymphoma49 (2008), 779.
112.
AlmanzarG. et al., Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells, Clinical Cancer Research15 (2009), 1954.
113.
GodefroyE. et al., Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals, Cancer Immunology, Immunotherapy56 (2007), 1183.
114.
BricardG. et al., Naturally acquired MAGE-A10-and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma, The Journal of Immunology174 (2005), 1709.
115.
AyyoubM. et al., CD4+ T cell responses to SSX-4 in melanoma patients, The Journal of Immunology174 (2005), 5092.
116.
NeumannF. et al., Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells, Blood106 (2005), 3105.
117.
HoganK.T. et al., Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma, Cancer Res64 (2004), 1157.
118.
MizukamiY. et al., Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma, Cancer Science99 (2008), 1448.
119.
Moreau-AubryA. et al., A processed pseudogene codes for a new antigen recognized by a CD8+ T cell clone on melanoma, Journal of Experimental Medicine191 (2000), 1617.
120.
ZhouQ. et al., A dendritic cell-based tumour vaccine for lung cancer: Full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro, Clinical & Experimental Immunology153 (2008), 392.
121.
EsfandiaryA. and Ghafouri-FardS., New york esophageal squamous cell carcinoma-1 and cancer immunotherapy, Immunotherapy7 (2015), 411.
122.
EsfandiaryA. and Ghafouri-FardS., MAGE-A3: an immunogenic target used in clinical practice, Immunotherapy7 (2015), 683.
123.
Ghafouri-FardS.ShamsiR.Seifi-AlanM.JavaheriM. and TabarestaniS., Cancer-testis genes as candidates for immunotherapy in breast cancer, Immunotherapy6 (2014), 165.
124.
FaramarziS. and Ghafouri-FardS., Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy, Immunotherapy9 (2017), 1019.
125.
Ghafouri-FardS. and Ghafouri-FardS., Immunotherapy in nonmelanoma skin cancer, Immunotherapy4 (2012), 499.
126.
FaramarziS. and Ghafouri-FardS., Melanoma: a prototype of cancer-testis antigen-expressing malignancies, Immunotherapy9 (Oct, 2017), 1103.
127.
Seifi-AlanM.ShamsiR. and Ghafouri-FardS., Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma, Immunotherapy10 (Apr, 2018), 411.
128.
Ghafouri-FardS.Seifi-AlanM.ShamsiR. and EsfandiaryA., Immunotherapy in multiple myeloma using cancer-testis antigens, Iran J Cancer Prev8 (Oct, 2015).
129.
Ghafouri-FardS. and ModarressiM.-H., Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy, Immunotherapy4 (2012), 59.
130.
SalmaninejadA. et al., Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers, Immunological Investigations45 (Oct, 2016), 619.
